WallStSmart

CubeSmart (CUBE)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 4073% more annual revenue ($47.35B vs $1.13B). CUBE leads profitability with a 28.9% profit margin vs 16.0%. SNY appears more attractively valued with a PEG of 3.76. SNY earns a higher WallStSmart Score of 51/100 (C-).

CUBE

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 6.0Quality: 3.0
Piotroski: 3/9Altman Z: 0.57

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CUBEUndervalued (+33.7%)

Margin of Safety

+33.7%

Fair Value

$58.21

Current Price

$40.46

$17.75 discount

UndervaluedFair: $58.21Overvalued
SNYUndervalued (+25.0%)

Margin of Safety

+25.0%

Fair Value

$62.70

Current Price

$43.31

$19.39 discount

UndervaluedFair: $62.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CUBE2 strengths · Avg: 9.5/10
Operating MarginProfitability
40.3%10/10

Strong operational efficiency at 40.3%

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$103.45B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

CUBE4 concerns · Avg: 3.5/10
P/E RatioValuation
28.2x4/10

Moderate valuation

Revenue GrowthGrowth
3.3%4/10

3.3% revenue growth

Debt/EquityHealth
1.263/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.762/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : CUBE

The strongest argument for CUBE centers on Operating Margin, Profit Margin. Profitability is solid with margins at 28.9% and operating margin at 40.3%.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : CUBE

The primary concerns for CUBE are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CUBE profiles as a value stock while SNY is a mature play — different risk/reward profiles.

CUBE carries more volatility with a beta of 1.11 — expect wider price swings.

SNY is growing revenue faster at 6.0% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

SNY scores higher overall (51/100 vs 49/100), backed by strong 16.0% margins. CUBE offers better value entry with a 33.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CubeSmart

REAL ESTATE · REIT - INDUSTRIAL · USA

CubeSmart is a self-managed and self-managed real estate investment trust.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?